cAMPfield Therapeutics, Inc., a clinical-stage biopharmaceutical company formed to develop well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, has launched with a US$180 million Series A financing to advance prifemilast (HY1999/HPP737), a once-daily oral PDE4 inhibitor, for the treatment of inflammatory bowel disease (IBD). The Series A financing was supported by top tier investors led by Frazier Life Sciences, and included Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital.
Latham & Watkins LLP advised cAMPfield in the transaction with a corporate team led by San Diego partners Matt Bush and Christian Hollweg, with associate Alex Stuart-Lovell. Advice was also provided on licensing matters by San Diego counsel Robert Yeh.
